Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (Review)

  • Authors:
    • Soichi Kojima
    • Masataka Okuno
    • Rie Matsushima-Nishiwaki
    • Scott L. Friedman
    • Hisataka Moriwaki
  • View Affiliations

  • Published online on: April 1, 2004     https://doi.org/10.3892/ijo.24.4.797
  • Pages: 797-805
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We here review therapeutic application of a synthetic analog of retinoids (vitamin A and its derivatives), named acyclic retinoid (AR), towards chemoprevention of hepatocellular carcinoma (HCC), and its underlying molecular mechanisms. A high incidence of post-therapeutic recurrence has become a major determinant of the prognosis of HCC, especially in the patients of hepatitis virus-infected cirrhosis. Oral supplementation of AR successfully prevented the recurrence of HCC, associated with a disappearance in serum levels of lectin-reactive α-fetoprotein (AFP-L3), a marker of occult cancer clones in the liver, suggesting eradication of latent malignant clones from patients' liver. This led us a novel concept of ‘clonal deletion’ with AR as an agent that is conceptually similar to cancer chemotherapy. HCC in cirrhotic patients contains lower levels of endogenous retinoids and simultaneously is insensitive to retinoic acid (RA) because of malfunction of its nuclear receptor, retinoid X receptor α (RXRα). In HCC tissues, RXRα is constitutively phosphorylated by the action of extracellular signal-regulated kinase (Erk), thereby losing its transactivation activity and becoming resistant to degradation via ubiquitin/proteasome pathway. This leads to accumulation of phospho-inactivated RXRα, that functions as a dominant negative receptor and interferes with transactivation by remaining normal RXRα. AR but not natural RA prevents phosphorylation of RXRα and restores the function of RXRα via down-regulating Ras/Erk system, making HCC cells sensitive to the endogenous ligand, 9-cis-RA. This may link to both caspase-dependent and -independent apoptosis of the cancer cells via induction of growth suppressor(s) such as p21CIP1 and/or apoptosis inducer(s) including tissue transglutaminase. AR also enhances the sensitivity of HCC cells to interferons-α and -β, and thereby indirectly promotes apoptosis induced by these interferons. In summary, our clinical experience and basic research together provide a strong rationale to use AR in the chemoprevention of HCC.

Related Articles

Journal Cover

April 2004
Volume 24 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kojima, S., Okuno, M., Matsushima-Nishiwaki, R., Friedman, S.L., & Moriwaki, H. (2004). Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (Review). International Journal of Oncology, 24, 797-805. https://doi.org/10.3892/ijo.24.4.797
MLA
Kojima, S., Okuno, M., Matsushima-Nishiwaki, R., Friedman, S. L., Moriwaki, H."Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (Review)". International Journal of Oncology 24.4 (2004): 797-805.
Chicago
Kojima, S., Okuno, M., Matsushima-Nishiwaki, R., Friedman, S. L., Moriwaki, H."Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (Review)". International Journal of Oncology 24, no. 4 (2004): 797-805. https://doi.org/10.3892/ijo.24.4.797